Pharmaceutical

J&Js Rybrevant plus Lazcluze combination gets FDA approval in NSCLC

J&J said the drug combination is now the first and only multitargeted, chemotherapy-free combination regimen proven to be superior to Tagrisso.

Aug 21, 2024 - 04:00
J&Js Rybrevant plus Lazcluze combination gets FDA approval in NSCLC
J&J said the drug combination is now the first and only multitargeted, chemotherapy-free combination regimen proven to be superior to Tagrisso.
Read the original article

Tags:

Previous Article

Adcendo and Multitude ink ADC deal potentially worth $1bn

Next Article

ReAlta secures FDA orphan drug and fast track designations for GvHD therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Anticipation rises for RSV rollout as positive data eme...

Feb 24, 2024

South Korean company Dong-A ST wins FDA approval for Stelara biosimilar

South Korean company Dong-A ST wins FDA approval for St...

Oct 12, 2024

STAT+: U.K. agency declines to recommend Eli Lilly’s Mounjaro for type 2 diabetes

STAT+: U.K. agency declines to recommend Eli Lilly’s Mo...

Jun 26, 2023